The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Myles Robert Minter - William Blair & Company L.L.C., Research Division - Analyst
: You're going to hate me but back on an Essential1 and the potential trial modifications here. Are you looking at increasing the patient enrollment
number? And also on the stats plan, considering it's now going to be an efficacy trial, how are you going to adjust for multiplicity between the
doses there? I only make mention of that because there's been some recent FDA interactions in the schizophrenia space where if not all doses are
positive, but it's not aligned with the stats plan, technically is not a positive trial. So what are your thoughts all around that?
Question: Myles Robert Minter - William Blair & Company L.L.C., Research Division - Analyst
: Just on Slide 8 of the data released this afternoon. It does look as if when those patients come off drug that they pretty much cannot draw in a
circle, but they kind of could at baseline. So I'm wondering what your theory is there? Is there a dependency that's developing on PRAX-944 or like
why would a patient that's come off drug not be able to draw that circle if they could at baseline? And I know that, that's just one patient. Did that
happen for everyone who had a response to 944 in the trial?
Question: Myles Robert Minter - William Blair & Company L.L.C., Research Division - Analyst
: On Slide 6, are you disclosing, I guess, how many patients actually had a response to PRAX-944 and then got randomized to placebo or for that
matter, didn't respond, they got randomized to placebo because theoretically, those patients should be flat over the 56-day period with their
tremor, right? So I'm just wondering how much they actually contributed to the data that we're seeing here?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MAY 09, 2022 / 8:30PM, PRAX.OQ - Q1 2022 Praxis Precision Medicines Inc Earnings Call
|
